文献速递消化道肿瘤与早癌消化内镜

粪便检测阳性患者结直肠肿瘤解剖位置:新罕布什尔结肠镜登记数据

Anatomical location of colorectal neoplasia in patients with positive stool test (multitarget stool deoxyribonucleic acid or fecal immunochemical test) results: data from the New Hampshire Colonoscopy Registry.
PubMed 文献 · Gastrointest Endosc · 2025-09-03

该横断面分析基于新罕布什尔结肠镜登记数据,比较mt-sDNA阳性、FIT阳性及未行粪便检测直接结肠镜三组人群结肠镜下肿瘤位置的分布。结果显示两种粪便检测阳性者左右侧进展期病变比例均高于直接结肠镜组,且mt-sDNA阳性者右侧进展期锯齿状息肉和右侧进展期病变风险显著高于FIT阳性者。

要点

  • FIT阳性与mt-sDNA阳性者左右侧进展期病变及进展期腺瘤比例均高于直接结肠镜组。
  • mt-sDNA阳性者右侧进展期锯齿状息肉风险显著高于FIT阳性者。
  • 粪便检测阳性者病变位置分布较直接结肠镜组更均匀,右侧病变检出比例相对更高。

核心结论

  • FIT阳性与mt-sDNA阳性均与左右侧进展期腺瘤检出增加相关,mt-sDNA阳性者右侧进展期锯齿状息肉风险更高。

研究设计与样本

  • 基于新罕布什尔结肠镜登记数据的横断面分析,比较mt-sDNA阳性(n=1176)、FIT阳性(n=584)与未行粪便检测直接结肠镜(n=68645)三组人群。

主要发现

  • 与直接结肠镜组相比,FIT阳性和mt-sDNA阳性者左右侧进展期病变及进展期腺瘤比例均更高(P < .001)。
  • mt-sDNA阳性者右侧进展期锯齿状息肉风险OR为3.21(95%CI 2.67-3.85),右侧进展期病变OR为3.13(95%CI 2.66-3.68),均以直接结肠镜为参照。
  • FIT阳性者右侧进展期锯齿状息肉OR为1.38(95%CI 0.99-1.99),右侧进展期病变OR为1.84(95%CI 1.43-2.37),均以直接结肠镜为参照。
  • 直接结肠镜组各结局右侧几率显著高于左侧,而FIT阳性和mt-sDNA阳性者病变在结肠各段分布更均匀。

临床怎么用

  • 粪便检测阳性后应完善结肠镜评估,尤其mt-sDNA阳性者需关注右侧结肠进展期锯齿状息肉的可能。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND AIMS: Data comparing the location of polyp yield in patients with positive stool test results can aid screening test selection. We conducted a cross-sectional analysis of New Hampshire Colonoscopy Registry data to compare the location, left versus right side of the colon, of neoplasia detected on colonoscopy after a multitarget stool DNA (mt-sDNA) test or a fecal immunochemical test (FIT), compared with a reference group undergoing colonoscopy without a stool test. METHODS: Our outcomes were advanced lesions (adenomas and/or serrated polyps, including cancer), advanced adenomas, or advanced serrated polyps stratified by location. We examined the prevalence of left- versus right-sided lesions across 3 cohorts. RESULTS: As compared to colonoscopy (n = 68,645), both FIT+ (n = 584) and mt-sDNA+ (n = 1176) patients had higher proportions of advanced lesions and advanced adenomas on both sides of the colon (P < .001). Mt-sDNA+ patients had significantly higher risks for right-sided advanced serrated polyps (odds ratio [OR], 3.21; 95% confidence interval [CI], 2.67-3.85; colonoscopy [reference]) and right-sided advanced lesions (OR, 3.13; 95% CI, 2.66-3.68; colonoscopy [reference]) as compared to FIT+ (advanced serrated polyps: OR, 1.38; 95% CI, 0.99-1.99 and advanced lesions: OR, 1.84; 95% CI, 1.43-2.37) or colonoscopy (reference). In our main analysis, the colonoscopy-only group had significantly higher odds of each outcome on the right side than the left side; in comparison, the odds for FIT+ and mt-sDNA+ patients were more evenly distributed throughout the colon. CONCLUSIONS: Our data suggest that FIT+ tests are associated with higher detection of both right- and left-sided advanced adenomas as compared to colonoscopy without a prior stool test. Furthermore, mt-sDNA+ patients had higher proportions of left- and right-sided advanced adenomas and advanced serrated polyps, particularly on the right side.

来源:Gastrointest Endosc,查看原文。版权归原作者所有。

引用

  1. Anderson JC, Hisey WM, Robinson CM, et al. Anatomical location of colorectal neoplasia in patients with positive stool test (multitarget stool deoxyribonucleic acid or fecal immunochemical test) results: data from the New Hampshire Colonoscopy Registry. Gastrointest Endosc. 2025. PMID: 40912495. doi:10.1016/j.gie.2025.08.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。